Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5390 News 


«12345678910111213...6970»
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Anti-M (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_857;    
    P3
    Measurement of AMH at end of treatment was comparably valuable to pretreatment and added slightly to the value of pretreatment sampling. Inclusion of ovarian function assessment by measuring AMH before commencing treatment can inform subsequent risk of ovarian function loss with value for fertility preservation counselling and treatment decisions.
  • ||||||||||  Which treatment is done in patients with metastatic breast cancer who received a prior treatment with CDK4/6 inhibitors? A real-world experience in a single italian Institution (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_788;    
    105 mBC patients, 32 of whom were treated with CD4/6 inhibitors plus letrozole and 73 treated with CDK4/6 inhibitors and fulvestrant were included in the study...1 (0.95%) patients was treated with a triplet chemotherapy regimen (cyclophosphamide+capecitabine +vinorelbine), 2 (1.9%) for whom the re-biopsy of the tumor resulted HER2 + were treated with taxol +pertuzumab +trastuzumab...The major part of them have been treated with chemotherapy alone or with combination of more chemotherapies. The evaluation of the patient response in relation to the different therapies is still ongoing as well as the effect of all the other therapies beyond the first line of treatment.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_773;    
    In the absence of any immediate indication for local therapy, the tyrosine-kinase inhibitor tucatinib combined with trastuzumab and capecitabine (TTC) is regarded as the preferred systemic treatment option for active BM, while data on the activity of antibody-drug conjugates (ADC) is limited...Adult patients with HER2-positive BC and active BM (newly diagnosed untreated or progressing after prior local therapy), prior treatment with trastuzumab and pertuzumab, ECOG performance status 0 or 1 without indication for immediate local therapy were accrued and received T-DXd until progression, inacceptable toxicity, or withdrawal for any other reason...Patients had received a median number of two prior treatment lines (range, 1-5), 60% had progressive brain metastases and 60% had received prior T-DM1...T-DXd did not impair QoL and neurocognitive functioning was maintained. Results therefore support the concept of ADCs as systemic therapy for active BM.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_769;    
    Alternative 1L treatments were CT plus H (26.5 vs 25.7%), H +/- P +/- endocrine therapy (8.2 vs 10.5%), T-DM1 (2 vs 9.2%), tyrosine kinase inhibitors-based regimens (7.5 vs 10.8%)...Although a significant proportion of pts with HER2+ MBC derive long-term benefit from anti-HER2 therapy, the treatment paradigm remains palliative, and it is unknown whether biomarkers may reliably predict exceptional response and guide future treatment. Ongoing work will explore whether genomic features vary between ExRes and ConRes.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Real-world efficacy of dual HER2-blockade in combination with anthracycline-containing and anthracycline-free neoadjuvant treatment in early breast cancer (BC). (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_738;    
    Neoadjuvant T-P plus chemotherapy with either anthracyclines or platinum therapy, demonstrated same efficacy and cardiac safety in our real-world study. pCR rates are lower in positive HR and HER2 positive 2+, needing more investigation with combination strategies including hormonotherapy, Our results are similar to data from randomized trials and other real-world efficacy studies, but we need more follow-up to identify late cardiotoxicity by anthracyclines and recurrences in positive HR tumors.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Delay in Diagnosis of Locally Advanced Breast Cancer during Lactation "Case Report" (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_660;    
    In conclusion, any breast abnormality reported by a pregnant or breastfeeding woman should not be neglected and assumed that it is a regular and physiological change until proven otherwise. Future proposals include guidelines for managing abnormal breast findings during pregnancy.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Valosin-containing protein (VCP)/p97: A novel breast cancer susceptibility gene? (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_656;    
    Further investigation into the role of VCP in tumorigenesis is warranted, and additional population studies are necessary to confirm VCP's role in breast cancer predisposition. Given that cancers with homologous recombination deficiencies benefit from PARP inhibitors and VCP is involved in the function of the PARP1 protein, patients with mutations in the VCP gene may benefit from PARP inhibition.
  • ||||||||||  COGNITION / -GUIDE  (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_642;    
    P, P2
    The theranostic COGNITION / -GUIDE platform moves the concept of precision oncology to a potentially curative but still high-risk stage of eBC following SOC NACT. Hence, this novel application in the field of precision oncology harbours the prospect to increase cure rates.
  • ||||||||||  Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
    Post-approval treatment patterns and tolerability of neratinib in HER2+ early-stage breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_623;    
    P=N/A, P2,
    Preliminary data suggest a similar safety profile for pts with/without prior pertuzumab. These datasets are limited by the fact that: (1) some pts were enrolled in the CONTROL trial prior to launch of adjuvant T-DM1 and pertuzumab; (2) the interval between T-DM1 launch in Europe and start of the ELEANOR study was relatively short; and (3) not all toxicity measures were formally graded.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Comprehensive characterization of genetic interactions in breast cancer reveals therapeutic vulnerabilities (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_593;    
    Overall, the consideration of genetic interactions may enhance our understanding of the heterogeneity in treatment response and complement ongoing efforts in precision oncology. Our study suggests that decision-making regarding genome-informed and genome-targeted treatment should extend beyond the scope of single driver alterations.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Impact of Discontinuation of Denosumab on Bone Health in Breast Cancer Patients (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_559;    
    It appears superior in reduction of SREs versus zoledronic acid (ZA) in established skeletal metastatic disease; thus, a preferred choice in the oncology setting...She was treated with neoadjuvant trastuzumab, pertuzumab, taxotere and carboplatin followed by bilateral mastectomy, and radiation to chest wall and L1...Bone modifying agents are often discontinued without consideration of the negative impact this may have. As this is a major survivorship issue, we document this case with literature review, to raise awareness for oncologists prescribing these medications.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_464;    
    P1/2
    Ibrutinib plus trastuzumab had a manageable safety profile; however, the CBR did not reach the protocol-specified goal of 28%, and these results do not support further clinical investigation. An in-depth evaluation of the immune effects of ibrutinib in these pts is ongoing.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Spatial PK/PD Model with HER2 Expression for Predicting Individual Tumor Response to T-DM1 (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_430;    
    In leveraging the SBS biophysical simulation platform, the spatial PK/PD model captures the individual variability in tumor growth rate, tumor perfusion, and drug disposition, all of which influence the treatment efficacy. The rate of target expression will highly influence response to an ADC, but the biophysical model demonstrates that features of the spatial tumor microenvironment also influence response.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Chemotherapy in geriatric patients with early stage HER2+ breast cancer: A National Cancer Database analysis. (Stars at Night Ballroom 3-4) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_384;    
    Of these, 3,052 (30.8%) received no-CT/mAbs, while 6,872 (69.2%) received CT/mAbs. Kaplan Meier curves comparing mortality by treatment in the whole sample showed that those in the CT/mAbs group had significantly improved survival, compared to the no-CT/mAbs group (Logrank P < 0.001).
  • ||||||||||  zanidatamab (ZW25) / Jazz
    Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (Stars at Night Ballroom 1-2) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_351;    
    Neoadjuvant zanidatamab demonstrates significant preliminary efficacy, (pCR/RCB-1 64%) with a good safety profile in patients with stage I node negative HER2+ BC. An update of efficacy and safety of all patients will be presented at the time of meeting
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns. (Pubmed Central) -  Oct 30, 2023   
    Toxic effects were also significantly overreported for trastuzumab-emtansine (cardiovascular malformation: ROR, 4.46 [95% CI, 1.02-19.52]) and lapatinib (intrauterine growth restriction: ROR, 7.68 [95% CI, 3.01-19.59]). In this case-control study of 328 individuals exposed to anti-ERBB2 agents during pregnancy, exposure was associated with a severe specific adverse pregnancy and fetal or newborn outcomes compared with exposure to other anticancer treatments.